Mechanism Research On Liuwei Dihuang Pill For Treatment Of Parkinson's Disease

Objective:Observation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPYP)-induced Parkinson's disease (Parkinson's disease,PD) model change in abnormal behavior in mice.To explore the pathogenesis of PD and the use of Liuweidihuangwan the mechanism of the treatment of PD.Methods:Selection of C57BL mice 50,male,weight 20 to 25 grams. MPTP dissolved in sterile saline,the dose of 25mg/kg by intraperitoneal injection of mice,1 day for 5 days to prepare PD model.The experimental animals were randomly divided into 5 groups,namely normal control group,model group,Madopar group Liuweidihuangwan group,the United States more than the fare Liuweidihuangwan group(referred to as post-treatment group 3).Model in mice to observe the process of change in abnormal behavior.Normal control group and model the success of the model group after oral administration in normal saline, Madopar group Liuweidihuangwan group,the United States more than the fare Liuweidihuangwan Group calculated in accordance with pharmacological dosage mice,administered in accordance with the volume of 0.5ml each preparation,1 times daily,for 4 weeks.Observation Liuweidihuangwan mouse model of Parkinson's disease on the performance of abnormal behavior, immunohistochemical determination of mouse substantia nigra tyrosine hydroxylase(Tyrosine hydroxylase,TH) changes in the number of positive cells;Determination of mouse substantia nigra part of superoxide dismutase(SOD),glutathione peroxidase(GSH-Px) activity and malondialdehyde(MDA) levels.Results:1.Behavior changes:Pole climbing time to study as an index of mouse behavior change,The model group compared wi th normal control group were significantly different(P＜0.0 1);Drug treatment group and two weeks after four weeks comp ared with the model group were significantly different(P＜0. 01);Treatment group showed no significant difference betwee n(P＞0.05),Drug treatment group after 4 weeks compared with the normal group the difference between(P＜0.05).Drum time to study as an index change behavior in mice,after treatme nt of 3 groups of mice behavior improved,compared with the model group were significantly different(P＜0.01).2.Substantia nigra of mouse brain neurons in the Department of the number of TH results:Compared with the normal group,model group,brain substantia nigra TH-positive neurons in the Department of the declining(P＜0.01);4 weeks in the administration,the treatment group the Department of substantia nigra TH-positive neurons increase in the number compared with the model group were significantly different(P＜0.01),Between the treatment group showed no statistical significance;administration after 4 weeks treatment group compared with the normal group E group no significant(P＞0.05),C,D groups were statistically significant differences(P＜0.05). 3.Murine substantia nigra part of SOD,GSH-Px activity and MDA levels:Brain GSH-Px,SOD content and the normal group, model group decreased significantly(P＜0.01),The MDA content in model group was significantly higher than normal(P＜0.01); Compared with model group,treatment group of mice brain SOD, GSH-Px levels,MDA levels(P＜0.01).Conclusion:LiuWei DiHuang pill of MPTP-induced PD model mouse nigral dopaminergic neurons has a protective effect,the administration Liuweidihuangwan can improve Parkinson's disease MPTP-induced motor dysfunction in mice,enhance the antioxidation ability of the body to reduce oxidative stress injury.